Skip to main content

Year: 2021

Crédit Agricole Consumer Finance is pursuing its ambition in the mobility market and acquires a stake in the leading French car distributor in Europe

         Crédit Agricole Consumer Finance is pursuing its ambitionin the mobility market and acquires a stakein the leading French car distributor in Europe Crédit Agricole Consumer Finance has affirmed its strategic ambition to develop car financing and encourage new forms of mobility, in line with the Crédit Agricole Group’s plan. In this context, CA Consumer Finance is investing €100 million in Cosmobilis, the holding company of ByMyCAR, the leading French car distribution group in Europe, which is expanding into new forms of mobility. At the same time, the two partners are entering into exclusive negotiations to create a pan-European joint venture for their automotive financing activities. Shared prioritiesThe Cosmobilis group’s activity is organised around four pillars:automobile distribution via a network of brand dealerships...

Continue reading

DZS Participates in O-RAN ALLIANCE Plugfest with Mavenir in Turin, Italy to Validate Open, Multi-Vendor 5G Stand Alone and 4G Macro Solutions

Successful interoperability demonstration of O-RAN network architecture at European OTIC labs features advanced 4G and 5G solutions from DZS, Mavenir, Dell, VMware, MTI, and Keysight PLANO, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) — DZS (NASDAQ: DZSI), a global leader in broadband connectivity platforms and communications software solutions, today announced its participation in the third Global O-RAN ALLIANCE PlugFest at the European Open Test and Integration Center (OTIC) in Turin, Italy hosted and sponsored by TIM. This testing validated multi-vendor 5G interoperability and end-to-end functional tests of O-RAN ALLIANCE specifications for 5G and 4G Radio Access Network (RAN) elements, including fronthaul, midhaul and backhaul interfaces between Radio Access Network equipment provided by DZS, Mavenir, Dell, VMware, Microelectronics...

Continue reading

Magnite to Present at the Needham Annual Growth Conference

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) — Magnite (Nasdaq: MGNI), the world’s largest independent sell-side advertising platform, today announced that management will present at the 24th Annual Virtual Needham Growth Conference on Wednesday, January 12th at 11:30 am eastern time. A live webcast of the presentation will be available in the “Events and Presentations” section of Magnite’s investor relations website at http://investor.magnite.com. The webcast will be available for replay following the conclusion of the live presentation for 180 days. About Magnite We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising platform. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands...

Continue reading

ThreeD Capital Inc. Acquires Securities of ZeU Technologies Inc.

TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm that invests in disruptive companies and promising junior resources companies, announces that ThreeD acquired ownership and control of 250,000 common shares (the “Subject Shares”) and 250,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of ZeU Technologies Inc. (the “Company” or “ZEU”) on December 20, 2021 (the “Acquisition”). The Subject Shares represented approximately 0.7% of all issued and outstanding common shares of the Company as of December 20, 2021. As a result of the Acquisition, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) increased by 2.6% from the last early warning report filed...

Continue reading

Melco Announces Partnership with Marriott International to Develop The First W Hotel at Studio City Phase Two in Macau

W Macau – Studio City exteriorW Macau – Studio City exteriorLiving RoomLiving RoomMACAU, Dec. 22, 2021 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment, a leading global developer, owner and operator of integrated resort facilities, announced today that it has entered into a strategic partnership with Marriott International to bring the W Hotels Worldwide brand to Studio City Phase 2, the thrilling new cinematically-themed entertainment and leisure destination in Macau. Scheduled to be open together with Studio City Phase 2 in December 2022, W Macau – Studio City is set to become an iconic addition in the world class leisure destination through its detail-driven, unexpected design, signature Whatever/Whenever® service and innovative programming. Situated in the heart of Cotai,...

Continue reading

MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

VYRA™ CoV2Flu Rapid Antigen Rapid Test.VYRA™ CoV2Flu Rapid Antigen Rapid Test.HALIFAX, Nova Scotia, Dec. 21, 2021 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRA™ product line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed to distinguish between SARS-CoV-2 and Influenza A or B infections. Furthermore, the Company takes advantage of the latest regulatory development surrounding the US FDA De Novo/510(k) clearance processes by applying for its COVID-19 products. The VYRA™ CoV2Flu Test simultaneously detects the Nucleocapsid antigens of SARS-CoV-2, Influenza A and B. Three distinguish results can be obtained in a matter of a few minutes. The test has demonstrated the ability...

Continue reading

Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study

MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as TLX101-CDx) as a complementary diagnostic agent to its TLX101 glioblastoma therapeutic candidate. The FET-PET in Glioblastoma (“FIG”) Study (ANZCTR Trial ID: ACTRN12619001735145) is a prospective, multicentre study which aims to definitively establish the role of FET-PET in the management of glioblastoma, a type of brain cancer. Glioblastoma...

Continue reading

Nevada Copper Operational Performance Continues to Accelerate

YERINGTON, Nev., Dec. 21, 2021 (GLOBE NEWSWIRE) — Nevada Copper Corp. (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) today provided a further positive operations update at its underground mine at the Company’s Pumpkin Hollow Project (the “Underground Mine”). December Underground Operations Highlights:Development Achieves Record RatesIn line with the continued ramp-up, the Company is on track to advance over 1,100 lateral equivalent feet of development in December. Development is running at the highest rate for 2021, and rates achieved month-to-date in December are almost 50% higher than November (representing almost a 100% increase since August 2021).Additional Mobile Equipment Delivered and CommissionedThe first planned bolter has been delivered and is now operating underground, resulting in...

Continue reading

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis (EoE). Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve...

Continue reading

Coro Global Inc. Expects to Return to Operations in 2022

Miami, Florida , Dec. 21, 2021 (GLOBE NEWSWIRE) — Coro Global Inc. (“Coro Global”) a Miami based fintech company announced today that it expects and hopes to resume operations by the end of Q1 2022 as well as to hold the Coro Global’s first annual shareholder meeting. Information regarding the logistics for the annual shareholder meeting and the agenda will be posted on Coro Global’s website (https://coro.global/) by the end of Q1 2022; the Board and management look forward to virtually gathering with our shareholders. “This year has proven once again that gold’s role as money is timeless. Inflation rates are soaring worldwide, and currencies are losing their value. Just this year alone Turkey’s currency the lira has lost over 50% of its value against gold and other currencies will soon face the same situation”, said David Dorr,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.